Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chi-Med Launches Fruquintinib, First China-Discovered Cancer Treatment

publication date: Nov 26, 2018

The first China-discovered treatment for cancer is now launched. Hutchison China MediTech (Chi-Med) and Lilly have begun China marketing of Elunate (fruquintinib), a VEGF-inhibitor approved to treat metastatic colorectal cancer. The two companies believe Elunate is a best-in-class VEGF drug. In 2013, Chi-Med and Lilly partnered to co-develop and market the candidate, which was approved by China regulators in September. More details....

Stock Symbols: (London/NSDQ: HCM) (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.